Anacor Pharma (ANAC) Tops Q4 EPS by 37c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St hits two-week lows as rising bond yields, Walmart results drag
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Anacor Pharmaceuticals (ANAC) PT Raised to $57 at Jefferies
March 13, 2015 8:41 AM EDTJefferies analyst David Steinberg reiterated a Buy rating and lifted is price target on Anacor Pharmaceuticals (NASDAQ: ANAC) to $57.00 (from $41.00) following Q4 results.
Steinberg commented, "ANAC reported a narrower Q4 loss primarily due to the earlier recognition of Kerydin revs (see details). More... More
Anacor Pharmaceuticals (ANAC) PT Raised to $60 at Wedbush
March 13, 2015 7:13 AM EDTWedbush analyst David Nierengarten reiterated an Outperform rating and boosted his price target on Anacor Pharmaceuticals (NASDAQ: ANAC) to $60.00 (from $50.00) after in 4Q14, its first full quarter of sales, Kerydin achieved about $10M in sales, beating the firm's $7.8M estimate.
Nierengarten commented... More
